BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jacobio Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jacobio Pharmaceuticals's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06959615-2145@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT06959615)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: A Phase I/IIa Study of JAB-23E73
  in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/jab-23e73#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06959615
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008288-2045@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glecirasib: Phase 2 readout est. (NCT06008288)
DESCRIPTION:Glecirasib\, phase 2.\nStudy: A Phase II Study Evaluating JAB-2
 1822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid 
 Tumors Harboring the KRAS p.G12C Mutation.\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gle
 cirasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06008288
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288205-2045@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05288205)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid 
 Tumors Harboring KRAS p.G12C Mutation\nEstimated primary completion: March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0528820
 5
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684157-2560@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JAB-8263: Phase 2 readout est. (NCT07684157)
DESCRIPTION:JAB-8263\, phase 2\, Rheumatoid Arthritis.\nStudy: A Phase IIa 
 Study of JAB-8263 in Patients With Active Rheumatoid Arthritis\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/jab-8263#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07684157
URL:https://assetmemo.bio/drug/jab-8263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05276726-2045@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05276726)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and ST
 K11 Co-mutation and Wild-type KEAP1\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05276726
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686682-2560@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:JAB-8263: Phase 1/2 readout est. (NCT04686682)
DESCRIPTION:JAB-8263\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fi
 rst-in-Human\, JAB-8263 in Adult Patients With Advanced Tumors\nEstimated 
 primary completion: January 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/jab-8263#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04686682
URL:https://assetmemo.bio/drug/jab-8263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973564-2145@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT06973564)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: JAB-23E73 in Adult Participants 
 With Advanced Solid Tumors With KRAS Alteration\nEstimated primary complet
 ion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/j
 ab-23e73#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06973564
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416410-2045@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Glecirasib: Phase 3 readout est. (NCT06416410)
DESCRIPTION:Glecirasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JAB-
 21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment 
 of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation\nEstimate
 d primary completion: 30 September 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/glecirasib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06416410
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640295-2145@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:JAB-23E73: Phase 1/2 readout est. (NCT07640295)
DESCRIPTION:JAB-23E73\, phase 1/2.\nStudy: Study of JAB-23E73 in Combinatio
 n With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Ge
 ne Alterations\nEstimated primary completion: 31 December 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/jab-23e73#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07640295
URL:https://assetmemo.bio/drug/jab-23e73#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
